(Albany, US) DelveInsight has launched a new report on “Cystinuria Pipeline Insight, 2020.”
“Cystinuria Pipeline Insight, 2020“ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cystinuria market. A detailed picture of the Cystinuria pipeline landscape is provided, which includes the disease overview and Cystinuria treatment guidelines.
The assessment part of the report embraces in-depth Cystinuria commercial assessment and clinical assessment of the Cystinuria pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cystinuria collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Companies covered: 1. Revive Therapeutics 2. Advicenne And many others
Drugs covered: 1. Bucillamine 2. ADV7103 And many others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/cystinuria-pipeline-insight
Scope of the report
“Cystinuria as a cause of 1–2% of stones observed in adults and about 10% of those occurring in children.”
Cystinuria is an inherited metabolic disorder characterized by the abnormal movement (transport) in the intestines and kidneys, of certain organic chemical compounds (amino acids). These include cystine, lysine, arginine, and ornithine. Excessive amounts of undissolved cysteine in the urine (cystinuria) cause the formation of stones (calculi) in the kidney, bladder, or ureter.
The primary objective of cystinuria treatment is to reduce the cystine concentration in the urine. The foremost aim of cystinuria treatment is to prevent the formation of the stone. The first line of treatment is high-fluid intake, which prevents the formation of new stones and dissolves the previously formed ones. By increasing the volume of urine, the concentration of cystine in the urine is reduced which prevents cystine from precipitating from the urine and forming stones.
Another strategy that has been attempted for cystinuria treatment is alkalization of the urine. The rationale is that in an alkaline (nonacidic) liquid, cystine tends to stay in solution and there it does no harm. Another approach for cystinuria treatment is the administration of D-penicillamine. D-penicillamine promotes the formation of cystine in a different chemical form (mixed disulfide), which is more soluble in the urine and is excreted easily.
Table of contents
1. Report Introduction
2. Cystinuria
2.1. Overview
2.2. History
2.3. Cystinuria Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Cystinuria Diagnosis
2.6.1. Diagnostic Guidelines
3. Cystinuria Current Treatment Patterns
3.1. Cystinuria Treatment Guidelines
4. Cystinuria – DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Cystinuria companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Cystinuria Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Cystinuria Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Cystinuria Late Stage Products (Phase-III)
7. Cystinuria Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cystinuria Discontinued Products
13. Cystinuria Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. Cystinuria Key Companies
15. Cystinuria Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Cystinuria Unmet Needs
18. Cystinuria Future Perspectives
19. Cystinuria Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Request for Detailed TOC: https://www.delveinsight.com/sample-request/cystinuria-pipeline-insight
About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/cystinuria-pipeline-insight